Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
≥,31572990,time to TOF,"With a TOF Watch SX device, the time to TOF ≥0.9 was recorded.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3123,DB00959,Methylprednisolone
≥,31572990,time to TOF,"However, in Group 2, time to TOF ≥0.9 was prolonged significantly when compared with the control group.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3124,DB00959,Methylprednisolone
,11294518,flow rate,"The mobile phase consisted of 16% isopropanol in water containing 0.1% trifluoroacetic acid, set at a flow rate of 1.2 mL/min.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),[ml] / [min],1.2,3291,DB00959,Methylprednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.2,3292,DB00959,Methylprednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.8,3293,DB00959,Methylprednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.6,3294,DB00959,Methylprednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.9,3295,DB00959,Methylprednisolone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,73,3296,DB00959,Methylprednisolone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,74,3297,DB00959,Methylprednisolone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,90,3298,DB00959,Methylprednisolone
,1445479,specific radioactivity,The ointments used for treatment on days 1 and 8 contained 14C-MPA with a specific radioactivity of 2.5 MBq/mg MPA.,Percutaneous absorption of methylprednisolone aceponate after single and multiple dermal application as ointment in male volunteers. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445479/),[Mbq] / [mg],2.5,6472,DB00959,Methylprednisolone
,30080939,plasma concentration,"The MP plasma concentration at 6 days for injection for the entire group (mean ± standard deviation [s.d.], pg/mL) was 96 ± 104.",Variability in plasma concentrations of methylprednisolone 6 days after intrasynovial injection of methylprednisolone acetate in racing horses: A field study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080939/),,96,6730,DB00959,Methylprednisolone
,14621866,trough level,"In conclusion, the therapeutic dose of FK 506 should be adjusted by monitoring the trough level in whole blood, the range of which might be recommended to be 15-20 ng/ml during the early phase after transplantation.",Japanese study of kidney transplantation: 1. Results of early phase II study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14621866/),[ng] / [ml],15-20,8112,DB00959,Methylprednisolone
,8668664,clearance,Increasing the dose from 2 to 10 mg/kg led to increased clearance from 5.9 to 10.5 (MPL) and from 1.8 to 2.3 L/hr/kg (L-MPL).,Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668664/),[l] / [h·kg],5.9 to 10.5,15307,DB00959,Methylprednisolone
,8668664,clearance,Increasing the dose from 2 to 10 mg/kg led to increased clearance from 5.9 to 10.5 (MPL) and from 1.8 to 2.3 L/hr/kg (L-MPL).,Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668664/),[l] / [h·kg],1.8 to 2.3,15308,DB00959,Methylprednisolone
,8668664,half-life,Liposomes without drug simultaneously administered with MPL caused partial prolongation of plasma steroid half-life (8.4 hr).,Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668664/),h,8.4,15309,DB00959,Methylprednisolone
,6626699,half-life,The disposition of methylprednisolone from plasma following intravenous (i.v.) infusion of its succinate ester appeared monoexponential with a mean half-life of 2.4 h and an apparent volume of distribution (Vd) of 50 l (0.87 l/kg).,Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),h,2.4,15550,DB00959,Methylprednisolone
,6626699,apparent volume of distribution (Vd),The disposition of methylprednisolone from plasma following intravenous (i.v.) infusion of its succinate ester appeared monoexponential with a mean half-life of 2.4 h and an apparent volume of distribution (Vd) of 50 l (0.87 l/kg).,Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),l,50,15551,DB00959,Methylprednisolone
,6626699,total body clearance (Cl),The total body clearance (Cl) averaged 15.12 l/h.,Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),[l] / [h],15.12,15552,DB00959,Methylprednisolone
,6626699,systemic availability (f,"No significant difference (p greater than 0.2) was observed when systemic availability (f, expressed in per cent) following administration of drug in capsule (f = 49.35 per cent) was compared with that obtained following the administration of drug in a suspension (f = 58.26 per cent).",Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),%,49.35,15553,DB00959,Methylprednisolone
,6626699,f,"No significant difference (p greater than 0.2) was observed when systemic availability (f, expressed in per cent) following administration of drug in capsule (f = 49.35 per cent) was compared with that obtained following the administration of drug in a suspension (f = 58.26 per cent).",Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),%,49.35,15554,DB00959,Methylprednisolone
,6626699,f,"No significant difference (p greater than 0.2) was observed when systemic availability (f, expressed in per cent) following administration of drug in capsule (f = 49.35 per cent) was compared with that obtained following the administration of drug in a suspension (f = 58.26 per cent).",Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),%,58.26,15555,DB00959,Methylprednisolone
,8105017,total body clearance,Interpatient variability in pharmacokinetic parameters of methylprednisolone was noted with a total body clearance of 240 +/- 112 mL/hr/Kg and half-life ranging from 2.2 to 3.9 hr.,CD4+/CD8+ lymphocyte patterns in renal transplant recipients receiving chronic methylprednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105017/),[ml] / [h·kg],240,16313,DB00959,Methylprednisolone
,8105017,half-life,Interpatient variability in pharmacokinetic parameters of methylprednisolone was noted with a total body clearance of 240 +/- 112 mL/hr/Kg and half-life ranging from 2.2 to 3.9 hr.,CD4+/CD8+ lymphocyte patterns in renal transplant recipients receiving chronic methylprednisolone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105017/),h,2.2 to 3.9,16314,DB00959,Methylprednisolone
,9115056,return AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],425,19357,DB00959,Methylprednisolone
,9115056,return AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),ml·ng,854,19358,DB00959,Methylprednisolone
,9115056,total AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],764,19359,DB00959,Methylprednisolone
,9115056,total AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],"1,230",19360,DB00959,Methylprednisolone
,9115056,suppression ratio,"The suppression ratio was significantly greater in the elderly men (mean, 0.38 versus 0.58 in young), which indicates a greater degree of adrenal suppression after administration of methylprednisolone.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),,0.38,19361,DB00959,Methylprednisolone
,9115056,suppression ratio,"The suppression ratio was significantly greater in the elderly men (mean, 0.38 versus 0.58 in young), which indicates a greater degree of adrenal suppression after administration of methylprednisolone.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),,0.58,19362,DB00959,Methylprednisolone
,9115056,AUC,"Exposure to methylprednisolone, as measured by AUC, was 554 +/- 215 ng.hr/kg (elderly) and 389 +/- 102 ng.hr/kg (young).",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [kg],554,19363,DB00959,Methylprednisolone
,9115056,AUC,"Exposure to methylprednisolone, as measured by AUC, was 554 +/- 215 ng.hr/kg (elderly) and 389 +/- 102 ng.hr/kg (young).",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [kg],389,19364,DB00959,Methylprednisolone
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.8,20431,DB00959,Methylprednisolone
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.4,20432,DB00959,Methylprednisolone
,12174030,half-life,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),h,2.2,22137,DB00959,Methylprednisolone
,12174030,clearance,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[ml] / [min],575,22138,DB00959,Methylprednisolone
,12174030,volume of distribution,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),l,106,22139,DB00959,Methylprednisolone
,12174030,concentration producing the half-maximum effect,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[ng] / [ml],1.5,22140,DB00959,Methylprednisolone
,12174030,Hill-coefficient,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),,1.2,22141,DB00959,Methylprednisolone
,12174030,total 24 h effect area (AUETC),"However, the total 24 h effect area (AUETC) of lymphocytes, and mainly CD4+ T-cells was significantly more suppressed (P = 0.008) with the divided dosage regimen than after the single dose (8422 +/- 2163 vs. 11,545 +/- 3020 h cells/microL).",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[cells·h] / [μl],8422,22142,DB00959,Methylprednisolone
,12174030,total 24 h effect area (AUETC),"However, the total 24 h effect area (AUETC) of lymphocytes, and mainly CD4+ T-cells was significantly more suppressed (P = 0.008) with the divided dosage regimen than after the single dose (8422 +/- 2163 vs. 11,545 +/- 3020 h cells/microL).",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[cells·h] / [μl],"11,545",22143,DB00959,Methylprednisolone
,3235500,Peak serum methylprednisone concentrations,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),[ng] / [ml],250,24265,DB00959,Methylprednisolone
,3235500,area under the curve ratio,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),,9.3,24266,DB00959,Methylprednisolone
,8633806,half-life,"Median half-life for MPA, as detected by HPLC, was 10.3 hours (range, 6.1 to 10.6) in the synovial space.","Plasma, urine, and synovial fluid disposition of methylprednisolone acetate and isoflupredone acetate after intra-articular administration in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633806/),h,10.3,29890,DB00959,Methylprednisolone
,8633806,half-life,"Median half-life for methylprednisolone, as detected by HPLC, was 10.4 (range, 9.9 to 32.1) hours.","Plasma, urine, and synovial fluid disposition of methylprednisolone acetate and isoflupredone acetate after intra-articular administration in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633806/),h,10.4,29891,DB00959,Methylprednisolone
,20430188,area-under-the-curve from 0 to 2 hours (AUC0-2),"The mean area-under-the-curve from 0 to 2 hours (AUC0-2) was 30.0+/-11.6 microg.h/mL (range, 7.8-60.7).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[h·μg] / [ml],30.0,31279,DB00959,Methylprednisolone
,20430188,trough,"Of 114 pharmacokinetic profiles, 40 (35%) AUC and 7 (6.1%) trough values were within the target value (30-60 microg.h/mL and 1.7-4.0 microg/mL, respectively).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],1.7-4.0,31280,DB00959,Methylprednisolone
,20430188,C0,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.01-4.46,31281,DB00959,Methylprednisolone
,20430188,C1/2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.14-36.86,31282,DB00959,Methylprednisolone
,20430188,C2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.79-18.19,31283,DB00959,Methylprednisolone
,3732369,clearance,The mean plasma methylprednisolone clearance of 337 ml X h-1 X kg-1 was independent of dose.,Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732369/),[ml] / [h·kg],337,31393,DB00959,Methylprednisolone
,3732369,volume of distribution,The steroid appears to moderately distribute into tissue spaces with a mean volume of distribution of 1.41 X kg-1.,Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732369/),1/[kg],1.41,31394,DB00959,Methylprednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],302.7,31407,DB00959,Methylprednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],383.2,31408,DB00959,Methylprednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],378.9,31409,DB00959,Methylprednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],214.0,31410,DB00959,Methylprednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1179.1,31411,DB00959,Methylprednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1687.0,31412,DB00959,Methylprednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],2209.5,31413,DB00959,Methylprednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],381.7,31414,DB00959,Methylprednisolone
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,86,31415,DB00959,Methylprednisolone
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,104,31416,DB00959,Methylprednisolone
,7652760,clearance,The 7 patients with a rejection within the first 10 days had a methylprednisolone clearance of 437 ml/min (162-756) that was significantly higher than the 220 ml/min (121-604) in the 22 patients without a rejection episode (P = 0.04).,Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),[ml] / [min],437,32175,DB00959,Methylprednisolone
,7652760,clearance,The 7 patients with a rejection within the first 10 days had a methylprednisolone clearance of 437 ml/min (162-756) that was significantly higher than the 220 ml/min (121-604) in the 22 patients without a rejection episode (P = 0.04).,Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),[ml] / [min],220,32176,DB00959,Methylprednisolone
,7652760,elimination half-life,"In the complete group of 18 patients having a transplant rejection episode within 6 months, the methylprednisolone elimination half-life after oral dosage was 2.5 hr (1.6-3.9) and significantly shorter than 2.9 hr (1.7-4.0) in 22 patients without rejections (P = 0.03).",Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),h,2.5,32177,DB00959,Methylprednisolone
shorter,7652760,elimination half-life,"In the complete group of 18 patients having a transplant rejection episode within 6 months, the methylprednisolone elimination half-life after oral dosage was 2.5 hr (1.6-3.9) and significantly shorter than 2.9 hr (1.7-4.0) in 22 patients without rejections (P = 0.03).",Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),h,2.9,32178,DB00959,Methylprednisolone
,3886255,relative bioavailability,"When methylprednisolone (80 mg) was also taken by mouth, the relative bioavailability of the tablets was 99%.",Kinetics of methylprednisolone and its hemisuccinate ester. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886255/),%,99,32753,DB00959,Methylprednisolone
,8159595,suppression half-life,"After the drug was administered, cortisol declined in a linear fashion with a mean suppression half-life of 2.4 +/- 0.9 hours.",Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),h,2.4,32908,DB00959,Methylprednisolone
,8159595,area under the curve (AUC-Cret),The return cortisol area under the curve (AUC-Cret) was noted in all patients and ranged from 57-987 ng.hr/ml.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],57-987,32909,DB00959,Methylprednisolone
,8159595,area under the curve,The total cortisol area under the curve was greater in patients who had been transplanted for longer than 2 years (1676 +/- 252 vs 836 +/- 405 ng.hr/ml; p < 0.05) compared with more recently transplanted patients.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],1676,32910,DB00959,Methylprednisolone
,8159595,area under the curve,The total cortisol area under the curve was greater in patients who had been transplanted for longer than 2 years (1676 +/- 252 vs 836 +/- 405 ng.hr/ml; p < 0.05) compared with more recently transplanted patients.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],836,32911,DB00959,Methylprednisolone
,8159595,clearance,Methylprednisolone clearance ranged from 100-1181 ml/hr/kg with a mean volume of distribution of 1.3 +/- 0.6 L/kg.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[ml] / [h·kg],100-1181,32912,DB00959,Methylprednisolone
,8159595,volume of distribution,Methylprednisolone clearance ranged from 100-1181 ml/hr/kg with a mean volume of distribution of 1.3 +/- 0.6 L/kg.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[l] / [kg],1.3,32913,DB00959,Methylprednisolone
,8159595,half-life,The methylprednisolone half-life ranged from 1.2-4.7 hours.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),h,1.2-4.7,32914,DB00959,Methylprednisolone
,2595785,total clearance,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ml] / [h·kg],379,35683,DB00959,Methylprednisolone
,2595785,volume of distribution,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[l] / [kg],1.4,35684,DB00959,Methylprednisolone
,2595785,plasma half-life,The mean plasma half-life was 2.7 +/- 1.1 hr.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),h,2.7,35685,DB00959,Methylprednisolone
,2595785,peak concentration,"When normalized to a 1 mg dose of methylprednisolone, the mean peak concentration at 1 hr was 10.0 +/- 3.5 ng/ml with an 8 hr concentration ranging from 0.3 to 5.5 ng/ml.",Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ng] / [ml],10.0,35686,DB00959,Methylprednisolone
,2804250,elimination half-life,The average elimination half-life for the prodrug was 3.7 min indicating rapid hydrolysis.,Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),min,3.7,35801,DB00959,Methylprednisolone
,2804250,total body clearance,"The total body clearance was 21 1h-1, the terminal half-life 2.8 h.",Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),1/[1h],21,35802,DB00959,Methylprednisolone
,2804250,terminal half-life,"The total body clearance was 21 1h-1, the terminal half-life 2.8 h.",Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),h,2.8,35803,DB00959,Methylprednisolone
,2804250,saliva/plasma ratio,The mean saliva/plasma ratio was 0.22.,Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),,0.22,35804,DB00959,Methylprednisolone
,3072558,saliva/plasma ratio,Methylprednisolone saliva levels paralleled plasma levels; the average saliva/plasma ratio was 0.22.,Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072558/),,0.22,36773,DB00959,Methylprednisolone
,3072558,Renal clearance,Renal clearance was 24 ml/min and not dose or prodrug dependent.,Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072558/),[ml] / [min],24,36774,DB00959,Methylprednisolone
,8653994,clearance,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[l] / [h·kg],0.298,37033,DB00959,Methylprednisolone
,8653994,clearance,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[l] / [h·kg],0.447,37034,DB00959,Methylprednisolone
,8653994,elimination half-life,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),h,2.20,37035,DB00959,Methylprednisolone
,8653994,elimination half-life,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),h,1.72,37036,DB00959,Methylprednisolone
,8653994,area under the response curve,"Greater net suppression of basophils was observed in the users of OC steroids (area under the response curve, 694 versus 401 ng x hr/ml).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[h·ng] / [ml],694,37037,DB00959,Methylprednisolone
,8653994,area under the response curve,"Greater net suppression of basophils was observed in the users of OC steroids (area under the response curve, 694 versus 401 ng x hr/ml).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[h·ng] / [ml],401,37038,DB00959,Methylprednisolone
,7667198,apparent prednisolone clearance,Single administration of CBG decreased apparent prednisolone clearance by 56% (155 to 66 ml/min/kg) and reduced apparent VSS by 35% (4.1 to 2.7 L/kg) (p < 0.001).,Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667198/),[ml] / [kg·min],155 to 66,39182,DB00959,Methylprednisolone
,2674406,limit of detection,"The limit of detection of both assays for PL and MP was 10 ng/mL in plasma and saliva and 25 ng/mL in urine, and of MPSS was 50 ng/mL in plasma.",Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674406/),[ng] / [ml],10,39628,DB00959,Methylprednisolone
,2674406,limit of detection,"The limit of detection of both assays for PL and MP was 10 ng/mL in plasma and saliva and 25 ng/mL in urine, and of MPSS was 50 ng/mL in plasma.",Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674406/),[ng] / [ml],25,39629,DB00959,Methylprednisolone
,2674406,limit of detection,"The limit of detection of both assays for PL and MP was 10 ng/mL in plasma and saliva and 25 ng/mL in urine, and of MPSS was 50 ng/mL in plasma.",Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674406/),[ng] / [ml],50,39630,DB00959,Methylprednisolone
,725320,t1/2,In vitro hydrolysis of methylprednisolone acetate at 37 degrees C in human whole blood is rapid (average t1/2 = 19 min).,Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),min,19,43905,DB00959,Methylprednisolone
,725320,bioavailabilities,"In one cat, the bioavailabilities of methylprednisolone acetate rectally was 13% and of methylprednisolone (alcohol) rectally was 26%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,13,43906,DB00959,Methylprednisolone
,725320,bioavailabilities,"In one cat, the bioavailabilities of methylprednisolone acetate rectally was 13% and of methylprednisolone (alcohol) rectally was 26%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,26,43907,DB00959,Methylprednisolone
,725320,bioavailabilities,"In the same cat, the bioavailabilities of methylprednisolone acetate orally was 93% and of methylprednisolone was 82%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,93,43908,DB00959,Methylprednisolone
,725320,bioavailabilities,"In the same cat, the bioavailabilities of methylprednisolone acetate orally was 93% and of methylprednisolone was 82%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,82,43909,DB00959,Methylprednisolone
,32190090,time of maximum concentration (T max),"After periocular injection, the time of maximum concentration (T max) of MPSS ranged from 0.25 h to 1 h in ocular tissues and was 0.25 h in plasma.",Pharmacokinetics after Periocular Methylprednisolone Sodium Succinate Injection in Rabbit Eyes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32190090/),h,0.25,44526,DB00959,Methylprednisolone
,32190090,time of maximum concentration (T max),"After periocular injection, the time of maximum concentration (T max) of MPSS ranged from 0.25 h to 1 h in ocular tissues and was 0.25 h in plasma.",Pharmacokinetics after Periocular Methylprednisolone Sodium Succinate Injection in Rabbit Eyes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32190090/),h,1,44527,DB00959,Methylprednisolone
,32190090,T max,"T max of MP in ocular tissues ranged from 0.5 h to 6 h, and T max of MP in plasma was 0.5 h.",Pharmacokinetics after Periocular Methylprednisolone Sodium Succinate Injection in Rabbit Eyes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32190090/),h,0.5,44528,DB00959,Methylprednisolone
,32190090,T max,"T max of MP in ocular tissues ranged from 0.5 h to 6 h, and T max of MP in plasma was 0.5 h.",Pharmacokinetics after Periocular Methylprednisolone Sodium Succinate Injection in Rabbit Eyes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32190090/),h,6,44529,DB00959,Methylprednisolone
,23089531,Trough levels,"Trough levels were fairly consistent at 7.9-18 ng·h/mL in all the patients included in this study, and this did not show variation with age or sex.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[h·ng] / [ml],7.9-18,45100,DB00959,Methylprednisolone
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],202-290,45101,DB00959,Methylprednisolone
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],60.5-171,45102,DB00959,Methylprednisolone
,23089531,AUC0-6,"The highest AUC0-6 was 246 ng/mL, observed at 4.5 mg b.d. dosage.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],246,45103,DB00959,Methylprednisolone
,9205818,input rate constant,Population modelling indicated that the only difference in MP pharmacokinetics between MP suleptanate and MP succinate was in the input rate constant (66.0 h-1 vs 5.5 h-1 respectively).,A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),1/[h],66.0,46742,DB00959,Methylprednisolone
,9205818,input rate constant,Population modelling indicated that the only difference in MP pharmacokinetics between MP suleptanate and MP succinate was in the input rate constant (66.0 h-1 vs 5.5 h-1 respectively).,A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),1/[h],5.5,46743,DB00959,Methylprednisolone
,9205818,half-life,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),h,2.7,46744,DB00959,Methylprednisolone
,9205818,half-life,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),h,3.0,46745,DB00959,Methylprednisolone
,9205818,steady-state AUC,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[h·ng] / [ml],2007.0,46746,DB00959,Methylprednisolone
,9205818,steady-state AUC,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[h·ng] / [ml],2321.0,46747,DB00959,Methylprednisolone
,9205818,steady-state Cmax,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[ng] / [ml],698.4,46748,DB00959,Methylprednisolone
,9205818,steady-state Cmax,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[ng] / [ml],647.8,46749,DB00959,Methylprednisolone
,9205818,relative bioavailability,In addition the differences in the pharmacokinetics for the prodrugs resulted in only a small difference in the relative bioavailability of MP for MP suleptanate (0.94) compared with MP succinate.,A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),,0.94,46750,DB00959,Methylprednisolone
,11604270,systemic clearance,The systemic clearance of DMP decreased approximately 5-fold (from 42.1+/-11.0 to 7.72+/-1.84 ml/h per kg) when the dose was increased from 2.5 to 30 mg/kg.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[ml] / [h·kg],42.1,48132,DB00959,Methylprednisolone
,11604270,systemic clearance,The systemic clearance of DMP decreased approximately 5-fold (from 42.1+/-11.0 to 7.72+/-1.84 ml/h per kg) when the dose was increased from 2.5 to 30 mg/kg.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[ml] / [h·kg],7.72,48133,DB00959,Methylprednisolone
,11604270,maximum velocity of elimination,The nonlinearity in the clearance of DMP could be adequately described by a Michaelis-Menten type elimination with a maximum velocity of elimination of 1.72 mg/h per kg and a constant of 24.9 microg/ml.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[mg] / [h·kg],1.72,48134,DB00959,Methylprednisolone
,11604270,constant,The nonlinearity in the clearance of DMP could be adequately described by a Michaelis-Menten type elimination with a maximum velocity of elimination of 1.72 mg/h per kg and a constant of 24.9 microg/ml.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[μg] / [ml],24.9,48135,DB00959,Methylprednisolone
,7516722,tissue-to-blood ratios,"Observed cecal and colonic tissue-to-blood ratios of 19:1 and 12:1, respectively, showed that this drug is extensively delivered to the large intestine even after subcutaneous administration.",Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: steady-state pharmacokinetics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7516722/),,12:1,51584,DB00959,Methylprednisolone
>,21976740,trough concentrations,"In 18 patients, mycophenolate mofetil (MMF) (adjusted to achieve blood mycophenolic acid trough concentrations > 2 μg/mL) was sequentially added, and 16 patients were converted to MMF monotherapy.",Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21976740/),[μg] / [ml],2,52509,DB00959,Methylprednisolone
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],1393,60429,DB00959,Methylprednisolone
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],2966,60430,DB00959,Methylprednisolone
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],28.7,60431,DB00959,Methylprednisolone
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],14.6,60432,DB00959,Methylprednisolone
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,2.28,60433,DB00959,Methylprednisolone
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,3.32,60434,DB00959,Methylprednisolone
,8645883,drug clearance,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),[ml] / [h·kg],174 to 638,60614,DB00959,Methylprednisolone
,8645883,volume of distribution,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),l,0.83 to 2.24,60615,DB00959,Methylprednisolone
,8645883,half-lives,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),h,1.20 to 3.02,60616,DB00959,Methylprednisolone
,8645883,C-AUC12,C-AUC12 ranged from 44.0 to 636 ng.h/ml.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),[h·ng] / [ml],44.0 to 636,60617,DB00959,Methylprednisolone
,29385232,plasma half-life,"2B3-201 was shown to have a plasma half-life between 24 and 37 h and caused a prolonged decrease in the lymphocyte count, adrenocorticotropic hormone and osteocalcin, and a rise in fasting glucose.",Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385232/),h,24 and 37,61204,DB00959,Methylprednisolone
,1827621,Total volume of distribution (Vss),"Total volume of distribution (Vss) of methylprednisolone was unchanged (about 120 L), but when normalized for total body weight, Vss per kilogram was less in obesity.",Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827621/),l,120,61228,DB00959,Methylprednisolone
,3245858,terminal half-life,"The terminal half-life of 2.7 +/- 1.3 h and tmax of 1.9 +/- 0.5 h are in agreement with corresponding data of other glucocorticoids, whereas the normalized plasma concentration and the volume of distribution are different.",[Pharmacokinetics of triamcinolone following oral administration]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245858/),h,2.7,61576,DB00959,Methylprednisolone
,3245858,tmax,"The terminal half-life of 2.7 +/- 1.3 h and tmax of 1.9 +/- 0.5 h are in agreement with corresponding data of other glucocorticoids, whereas the normalized plasma concentration and the volume of distribution are different.",[Pharmacokinetics of triamcinolone following oral administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245858/),h,1.9,61577,DB00959,Methylprednisolone
,2347663,peak values,"Sham dialysis did not apparently influence serum MP levels, as shown by similar peak values in patients undergoing sham dialysis (203 micrograms/ml +/- SEM 33) and in patients off dialysis (177 micrograms/ml +/- 42).",Complement activated leucopenia during hemodialysis: effect of pulse methyl-prednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2347663/),[μg] / [ml],203,62837,DB00959,Methylprednisolone
,2347663,peak values,"Sham dialysis did not apparently influence serum MP levels, as shown by similar peak values in patients undergoing sham dialysis (203 micrograms/ml +/- SEM 33) and in patients off dialysis (177 micrograms/ml +/- 42).",Complement activated leucopenia during hemodialysis: effect of pulse methyl-prednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2347663/),[μg] / [ml],177,62838,DB00959,Methylprednisolone
,8247916,clearance,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[ml] / [h·kg],234,64886,DB00959,Methylprednisolone
,8247916,clearance,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[ml] / [h·kg],472,64887,DB00959,Methylprednisolone
,8247916,volume of distribution,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[l] / [kg],0.3-2.0,64888,DB00959,Methylprednisolone
,8247916,volume of distribution,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[l] / [kg],0.8-2.0,64889,DB00959,Methylprednisolone
,8247916,elimination rate constant,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),1/[h],0.13-0.41,64890,DB00959,Methylprednisolone
,8247916,elimination rate constant,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),1/[h],0.27-0.42,64891,DB00959,Methylprednisolone
,8247916,half-life,The mean half-life of 3.4 +/- 1.4 hours in black patients compared with 2.1 +/- 0.3 hours in white patients approached statistical significance (p < 0.08).,Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),h,3.4,64892,DB00959,Methylprednisolone
,8247916,half-life,The mean half-life of 3.4 +/- 1.4 hours in black patients compared with 2.1 +/- 0.3 hours in white patients approached statistical significance (p < 0.08).,Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),h,2.1,64893,DB00959,Methylprednisolone
,31197020,plasma binding,The plasma binding of DEX and MPL was linear with moderate binding (60.5% and 82.5%) in male and female rats.,"Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197020/),%,60.5,65927,DB00959,Methylprednisolone
,31197020,plasma binding,The plasma binding of DEX and MPL was linear with moderate binding (60.5% and 82.5%) in male and female rats.,"Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197020/),%,82.5,65928,DB00959,Methylprednisolone
,1880717,availability,Incomplete availability of MP from iv MS (52-55%) and from the oral dose (10%) was found.,Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,52-55,67771,DB00959,Methylprednisolone
,1880717,availability,Incomplete availability of MP from iv MS (52-55%) and from the oral dose (10%) was found.,Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,10,67772,DB00959,Methylprednisolone
,1880717,hepatic extraction,"Extensive hepatic extraction of MP (84%) occurred at the low dose, but decreased to 48% at the high dose, supporting in vivo observations of high CL and nonlinearity.",Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,84,67773,DB00959,Methylprednisolone
,1880717,hepatic extraction,"Extensive hepatic extraction of MP (84%) occurred at the low dose, but decreased to 48% at the high dose, supporting in vivo observations of high CL and nonlinearity.",Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,48,67774,DB00959,Methylprednisolone
,1880717,Extraction,"Extraction of MS was also high (83%), but MP availability was slight (8%).",Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,83,67775,DB00959,Methylprednisolone
,1880717,fraction of MS metabolized,The MS and MP data were fitted to a sequential first-pass model yielding an average fraction of MS metabolized-to-MP value of 0.22.,Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),,0,67776,DB00959,Methylprednisolone
,28239897,specific clearance,"The data were best described by a two-compartment model comprising linear nonspecific clearance of 0.252 [95% confidence interval (CI): 0.227-0.279] l day-1 and time-varying specific clearance of 0.278 (95% CI: 0.181-0.390) l day-1 , corresponding to target-mediated drug disposition of rituximab.",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),[l] / [d],0.278,68234,DB00959,Methylprednisolone
,28239897,Rate constant of specific clearance decay,"Rate constant of specific clearance decay was 0.143 day-1 (95% CI: 0.0478-0.418) in patients with no disease progression, while in patients with disease progression it was 82.2% lower (95% CI: 33.4-95.0).",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),1/[d],0.143,68235,DB00959,Methylprednisolone
,8406379,peak plasma levels,The plasma pharmacokinetics were described by a one-compartment open model with peak plasma levels of 6.9 +/- 2.5 micrograms/ml.,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),[μg] / [ml],6.9,69689,DB00959,Methylprednisolone
,8406379,relative oral bioavailability,Mean relative oral bioavailability was generally high (91 +/- 27 per cent).,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),%,91,69690,DB00959,Methylprednisolone
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],160,69779,DB00959,Methylprednisolone
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],148,69780,DB00959,Methylprednisolone
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,5.03,69781,DB00959,Methylprednisolone
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,6.18,69782,DB00959,Methylprednisolone
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.23,69783,DB00959,Methylprednisolone
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.19,69784,DB00959,Methylprednisolone
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.79,69785,DB00959,Methylprednisolone
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.84,69786,DB00959,Methylprednisolone
,2179900,formation rate constant,The prodrug ester MPHS yields MP with an average formation rate constant of 0.70 +/- 0.29 hr-1.,Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2179900/),1/[h],0.70,69912,DB00959,Methylprednisolone
,26103520,maximum dose,"The median maximum dose of MMF was 60 mg/kg/day (range, 34-107).",Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26103520/),[mg] / [d·kg],60,80473,DB00959,Methylprednisolone
<,15257072,AUC(0-4),"Patients with an AUC(0-4) < 4400 microg x h/L at both PK sampling periods in the first 3 weeks posttransplant had an adjusted relative risk of 48.4% to suffer an acute rejection episode (ARE), whereas in patients with at least 1 AUC0-4 above this threshold, the adjusted relative risk for an ARE was only 13.1% (P < 0.02).",Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257072/),[h·μg] / [l],4400,81067,DB00959,Methylprednisolone
,8536129,tmax,tmax ranged from one to four hours (mean + SD; 2.8 + 1.3) and fluctuated in both intra- and interindividual measurements.,Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536129/),h,2.8,84329,DB00959,Methylprednisolone
greater,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,500,87809,DB00959,Methylprednisolone
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,15,87810,DB00959,Methylprednisolone
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,23,87811,DB00959,Methylprednisolone
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.49,87812,DB00959,Methylprednisolone
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.27,87813,DB00959,Methylprednisolone
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.16,87814,DB00959,Methylprednisolone
,8227476,clearance (CL),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[ml] / [h·kg],495,91971,DB00959,Methylprednisolone
,8227476,clearance (CL),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[ml] / [h·kg],1389,91972,DB00959,Methylprednisolone
,8227476,volume of distribution (Vss),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[1] / [kg],0.35,91973,DB00959,Methylprednisolone
,8227476,"elimination half-life, t1/2 beta","The elimination half-life, t1/2 beta, was significantly longer in CLD (0.61 vs. 0.32 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,0.61,91974,DB00959,Methylprednisolone
,8227476,"elimination half-life, t1/2 beta","The elimination half-life, t1/2 beta, was significantly longer in CLD (0.61 vs. 0.32 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,0.32,91975,DB00959,Methylprednisolone
,8227476,percent recovery,The percent recovery of unchanged MPHS in urine was similar (about 9%) in both groups.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),%,9,91976,DB00959,Methylprednisolone
,8227476,clearance,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[l] / [h·kg],370,91977,DB00959,Methylprednisolone
,8227476,Vss,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[l] / [kg],1.3,91978,DB00959,Methylprednisolone
,8227476,t1/2 beta,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,3.0,91979,DB00959,Methylprednisolone
,8227476,suppression t1/2,The suppression t1/2 of cortisol after MPHS was longer (3.9 vs. 1.9 hr) indicating metabolic pathways for cortisol and MP are affected differently in CLD.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,3.9,91980,DB00959,Methylprednisolone
,8227476,suppression t1/2,The suppression t1/2 of cortisol after MPHS was longer (3.9 vs. 1.9 hr) indicating metabolic pathways for cortisol and MP are affected differently in CLD.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,1.9,91981,DB00959,Methylprednisolone
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.60,96350,DB00959,Methylprednisolone
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.43,96351,DB00959,Methylprednisolone
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.19,96352,DB00959,Methylprednisolone
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.14,96353,DB00959,Methylprednisolone
,8222483,clearance,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[l] / [h·kg],0.45,96565,DB00959,Methylprednisolone
,8222483,clearance,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[l] / [h·kg],0.29,96566,DB00959,Methylprednisolone
,8222483,elimination half-life,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),h,1.7,96567,DB00959,Methylprednisolone
,8222483,elimination half-life,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),h,2.6,96568,DB00959,Methylprednisolone
,8222483,50% inhibitory concentration (IC50),"A significantly smaller 50% inhibitory concentration (IC50) value (0.1 versus 1.7 ng/ml) was seen in the women for suppression of cortisol secretion, indicating increased sensitivity.",Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[ng] / [ml],0.1,96569,DB00959,Methylprednisolone
,8222483,50% inhibitory concentration (IC50),"A significantly smaller 50% inhibitory concentration (IC50) value (0.1 versus 1.7 ng/ml) was seen in the women for suppression of cortisol secretion, indicating increased sensitivity.",Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[ng] / [ml],1.7,96570,DB00959,Methylprednisolone
,9865456,clearance,"A slower clearance of methylprednisolone was noted in the elderly (mean: 256 mL/hr/Kg) than in the young men (mean: 359 mL/hr/Kg; p < 0.05) during Phase II with no significant difference found between groups for volume of distribution, elimination rate constant or half-life.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),[ml] / [h·kg],256,97722,DB00959,Methylprednisolone
,9865456,clearance,"A slower clearance of methylprednisolone was noted in the elderly (mean: 256 mL/hr/Kg) than in the young men (mean: 359 mL/hr/Kg; p < 0.05) during Phase II with no significant difference found between groups for volume of distribution, elimination rate constant or half-life.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),[ml] / [h·kg],359,97723,DB00959,Methylprednisolone
,9865456,co,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.36,97724,DB00959,Methylprednisolone
,9865456,co,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.58,97725,DB00959,Methylprednisolone
,9865456,suppression ratio,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.36,97726,DB00959,Methylprednisolone
,9865456,suppression ratio,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.58,97727,DB00959,Methylprednisolone
,8549229,half-life,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),h,1.150,98700,DB00959,Methylprednisolone
,8549229,excretion constant,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ke] / [h],0.686,98701,DB00959,Methylprednisolone
,8549229,volume of distribution,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [kg],607,98702,DB00959,Methylprednisolone
,8549229,clearance rate,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [h·kg],374,98703,DB00959,Methylprednisolone
,2225699,clearance,"Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [+/- SD] 380 +/- 100 ml/min/1.73 m2) without an identifiable cause.",Monitoring glucocorticoid therapy: a pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225699/),[ml] / [1.73·m2·min],565 to 837,104355,DB00959,Methylprednisolone
,2225699,clearance,"Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [+/- SD] 380 +/- 100 ml/min/1.73 m2) without an identifiable cause.",Monitoring glucocorticoid therapy: a pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225699/),[ml] / [1.73·m2·min],380,104356,DB00959,Methylprednisolone
,3361533,Vd,"Pharmacokinetic variables for methylprednisolone were Vd of 69.9 l, t1/2 of 2.96 h, total plasma clearance of 17.5 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),l,69.9,110205,DB00959,Methylprednisolone
,3361533,t1/2,"Pharmacokinetic variables for methylprednisolone were Vd of 69.9 l, t1/2 of 2.96 h, total plasma clearance of 17.5 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),h,2.96,110206,DB00959,Methylprednisolone
,3361533,total plasma clearance,"Pharmacokinetic variables for methylprednisolone were Vd of 69.9 l, t1/2 of 2.96 h, total plasma clearance of 17.5 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),[l] / [h],17.5,110207,DB00959,Methylprednisolone
,3361533,Vd,"Pharmacokinetic variables for prednisolone were Vd of 47.5 l, t1/2 of 3.08 h and total plasma clearance of 11.3 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),l,47.5,110208,DB00959,Methylprednisolone
,3361533,t1/2,"Pharmacokinetic variables for prednisolone were Vd of 47.5 l, t1/2 of 3.08 h and total plasma clearance of 11.3 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),h,3.08,110209,DB00959,Methylprednisolone
,3361533,total plasma clearance,"Pharmacokinetic variables for prednisolone were Vd of 47.5 l, t1/2 of 3.08 h and total plasma clearance of 11.3 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),[l] / [h],11.3,110210,DB00959,Methylprednisolone
,21998684,t(1/2),"These principles allow fabrication of formulations that exhibit either a fast, second-order (t(1/2) ~1 h), or a slow, zero-order release rate (t(1/2) ~ 50 h) kinetics.",Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21998684/),h,1,110829,DB00959,Methylprednisolone
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,15,111482,DB00959,Methylprednisolone
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,25,111483,DB00959,Methylprednisolone
,11304898,CLo,"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),[l] / [h],13.2,112437,DB00959,Methylprednisolone
,11304898,CLmax,"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),[l] / [h],25.0,112438,DB00959,Methylprednisolone
,11304898,time of half-maximal increase in CL (T50),"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),h,41.1,112439,DB00959,Methylprednisolone
,11304898,gamma (Hill coefficient),"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),,3.8,112440,DB00959,Methylprednisolone
,11304898,volume of distribution (Vd),"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),l,137,112441,DB00959,Methylprednisolone
,3207561,renal clearance,2. The mean (+/- s.e. mean) renal clearance of sulphadimidine was increased from 0.03 +/- 0.01 to 0.07 +/- 0.02 ml min-1 kg-1 (P = 0.01) following the administration of intra-articular steroid.,Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207561/),[ml] / [kg·min],0.03,115005,DB00959,Methylprednisolone
,3207561,renal clearance,2. The mean (+/- s.e. mean) renal clearance of sulphadimidine was increased from 0.03 +/- 0.01 to 0.07 +/- 0.02 ml min-1 kg-1 (P = 0.01) following the administration of intra-articular steroid.,Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207561/),[ml] / [kg·min],0.07,115006,DB00959,Methylprednisolone
,1838490,biodisponibility,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),%,60,126480,DB00959,Methylprednisolone
,1838490,clearance,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),[ml] / [min],20,126481,DB00959,Methylprednisolone
,1838490,elimination half life,"The pharmacokinetics of the drug are as follows: absorption begins about 30 minutes after the administration per os, its biodisponibility is about 60%, its clearance: 20 ml/minute and its elimination half life about 3 hours.","[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1838490/),h,3,126482,DB00959,Methylprednisolone
,7494809,Maximum concentrations,Maximum concentrations of 21-desacetyldeflazacort averaged 116 ng/ml and were observed after 1.3 h.,Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494809/),[ng] / [ml],116,129146,DB00959,Methylprednisolone
,7494809,area under the curve,"The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h.",Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494809/),[ng] / [h·ml],280,129147,DB00959,Methylprednisolone
,7494809,terminal half-life,"The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h.",Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494809/),h,1.3,129148,DB00959,Methylprednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],19.5,130407,DB00959,Methylprednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],27.7,130408,DB00959,Methylprednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],20,130409,DB00959,Methylprednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],31,130410,DB00959,Methylprednisolone
,7876403,clearance,"After multiple dosing, mean clearance values increased from 31.1 to 44.7 L/hr for sodium succinate dosing, and from 31.5 to 46.0 L/hr for suleptanate dosing.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],31.1 to 44.7,130411,DB00959,Methylprednisolone
,7876403,clearance,"After multiple dosing, mean clearance values increased from 31.1 to 44.7 L/hr for sodium succinate dosing, and from 31.5 to 46.0 L/hr for suleptanate dosing.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],31.5 to 46.0,130412,DB00959,Methylprednisolone
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],48.0,134416,DB00959,Methylprednisolone
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],38.9,134417,DB00959,Methylprednisolone
,17990084,solubility,"Being formulated with 6% PM, MP had higher solubility (219.6 +/- 3.6 microg/ml) and release rate (11.1 +/- 0.4 ng min(1/2)) at 37 degrees C.",Bioavailability effect of methylprednisolone by polymeric micelles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),[μg] / [ml],219.6,135300,DB00959,Methylprednisolone
,17990084,release rate,"Being formulated with 6% PM, MP had higher solubility (219.6 +/- 3.6 microg/ml) and release rate (11.1 +/- 0.4 ng min(1/2)) at 37 degrees C.",Bioavailability effect of methylprednisolone by polymeric micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),[min(1·ng] / [2],11.1,135301,DB00959,Methylprednisolone
,17990084,plasma half-lives (t (1/2)),PM formulation markedly increased (7-fold) the plasma half-lives (t (1/2)) of MP (from 76.1 +/- 8.0 to 514.3 +/- 70.0 min).,Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,76.1,135302,DB00959,Methylprednisolone
,17990084,plasma half-lives (t (1/2)),PM formulation markedly increased (7-fold) the plasma half-lives (t (1/2)) of MP (from 76.1 +/- 8.0 to 514.3 +/- 70.0 min).,Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,514.3,135303,DB00959,Methylprednisolone
,17990084,SC t (1/2),"In addition, the SC t (1/2) of MP/PM also increased from 278 to 528 min.",Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,278,135304,DB00959,Methylprednisolone
,17990084,SC t (1/2),"In addition, the SC t (1/2) of MP/PM also increased from 278 to 528 min.",Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,528,135305,DB00959,Methylprednisolone
,12006542,time required to reach the maximum plasma drug concentration (t(max)),"Our findings indicate that LFM-A13 is quickly absorbed, with the time required to reach the maximum plasma drug concentration (t(max)) being 10-18 min after i.p. administration with nearly complete bioavailability.","In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,10-18,143386,DB00959,Methylprednisolone
,12006542,elimination half-life,LFM-A13 had an elimination half-life of 17-32 min after i.p. administration at dose levels of 10-50 mg/kg.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,17-32,143387,DB00959,Methylprednisolone
,12006542,survival time,LFM-A13 prolonged the median survival time of VPL-treated mice from 37 to 58 days.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),d,37 to 58,143388,DB00959,Methylprednisolone
,22777155,Area under the time-concentration curve,Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),h·kg·mg·ml·μg,3-13,143749,DB00959,Methylprednisolone
,22777155,maximum concentrations (Cmax),Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),kg·mg·ml·μg,0.37 and 2.5,143750,DB00959,Methylprednisolone
,22777155,trough concentrations (C0),Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),kg·mg·ml·μg,0.13 and 1.1,143751,DB00959,Methylprednisolone
,22777155,elimination half-lives,The elimination half-lives were 1.9-10.3 hours.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),h,1.9-10.3,143752,DB00959,Methylprednisolone
,22777155,Apparent volume of distribution (VD/F),"Apparent volume of distribution (VD/F) and apparent clearance (Cl/F) were 23-159 L and 4.7-28.7 L/h, respectively.",The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),l,23-159,143753,DB00959,Methylprednisolone
,22777155,apparent clearance (Cl/F),"Apparent volume of distribution (VD/F) and apparent clearance (Cl/F) were 23-159 L and 4.7-28.7 L/h, respectively.",The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),[l] / [h],4.7-28.7,143754,DB00959,Methylprednisolone
,3517294,availability,"After intravenous methylprednisolone sodium succinate administration, methylprednisolone was released rapidly but the extent of availability was rather low (43.6%).","Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517294/),%,43.6,143995,DB00959,Methylprednisolone
,3517294,half-time of absorption,"After intramuscular administration of methylprednisolone acetate, its absorption was slow (half-time of absorption, 69.04 h) and the availability of the released methylprednisolone was low (42.7%).","Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517294/),h,69.04,143996,DB00959,Methylprednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,375.4,145039,DB00959,Methylprednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,160.8,145040,DB00959,Methylprednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,361.2,145041,DB00959,Methylprednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,147.0,145042,DB00959,Methylprednisolone
,1184723,MCR,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),[l] / [d],383,149337,DB00959,Methylprednisolone
,1184723,volume of distribution,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),l,61,149338,DB00959,Methylprednisolone
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,424,149339,DB00959,Methylprednisolone
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,977,149340,DB00959,Methylprednisolone
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,149,149341,DB00959,Methylprednisolone
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,69,149342,DB00959,Methylprednisolone
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,2.1,150097,DB00959,Methylprednisolone
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,4.8,150098,DB00959,Methylprednisolone
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],11.0,150099,DB00959,Methylprednisolone
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],117,150100,DB00959,Methylprednisolone
,4009439,Overall recovery,Overall recovery was 80%.,Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009439/),%,80,157699,DB00959,Methylprednisolone
,4009439,Cmax,Cmax values ranged from 40 to 150 ng/mL with tmax values of 1-2 h.,Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009439/),[ng] / [ml],40 to 150,157700,DB00959,Methylprednisolone
,4009439,tmax,Cmax values ranged from 40 to 150 ng/mL with tmax values of 1-2 h.,Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009439/),h,1-2,157701,DB00959,Methylprednisolone
,4009439,half-life,The harmonic mean half-life of fluoxymesterone was 2.0 h.,Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009439/),h,2.0,157702,DB00959,Methylprednisolone
,11835067,clearance,Methylprednisolone clearance was approximately 280 ml h(minus sign1) kg(minus sign1) and volume of distribution was about 1.1 L kg(minus sign1).,The Pharmacokinetics and Pharmacodynamics of Methylprednisolone in Chronic Renal Failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835067/),h·ml,280,162852,DB00959,Methylprednisolone
,11835067,volume of distribution,Methylprednisolone clearance was approximately 280 ml h(minus sign1) kg(minus sign1) and volume of distribution was about 1.1 L kg(minus sign1).,The Pharmacokinetics and Pharmacodynamics of Methylprednisolone in Chronic Renal Failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835067/),kg·l,1.1,162853,DB00959,Methylprednisolone
,17593325,bioavailability,The pharmacokinetics of MPL showed bi-exponential disposition with two first-order absorption components from the injection site and bioavailability was 21%.,Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593325/),%,21,165032,DB00959,Methylprednisolone
,16579759,transfer half-life (t(1/2t)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,1.7,165762,DB00959,Methylprednisolone
,16579759,elimination half-life (t(1/2e)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,19.2,165763,DB00959,Methylprednisolone
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],7.26,165764,DB00959,Methylprednisolone
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],0.11,165765,DB00959,Methylprednisolone
,21850665,peak level (C(max),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[ng] / [ml],13.7,166590,DB00959,Methylprednisolone
,21850665,AUC(0-72 h),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[h·ng] / [ml],198,166591,DB00959,Methylprednisolone
,21850665,C(max),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[ng] / [ml],18.4,166592,DB00959,Methylprednisolone
,21850665,AUC(0-72 h),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[h·ng] / [ml],943,166593,DB00959,Methylprednisolone
,21850665,t(max),"The administration of MP-PLGA MS resulted in a rapid increase in the MP concentration at 30 min, with a t(max) at 0.8 ± 0.3 h.",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),h,0.8,166594,DB00959,Methylprednisolone
,21850665,t(max),"Instead, for the MPA suspension the t(max) was 32.0 ± 13.9 h.",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),h,32.0,166595,DB00959,Methylprednisolone
,2655680,half-life,"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),h,1.93,168300,DB00959,Methylprednisolone
,2655680,mean residence time (MRT),"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),h,3.50,168301,DB00959,Methylprednisolone
,2655680,mean residence time (MRT),"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),1/[kg·lh],0.45,168302,DB00959,Methylprednisolone
,2655680,volume of distribution at steady state (Vss),"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),[1] / [kg],1.5,168303,DB00959,Methylprednisolone
,2655680,bioavailability,3. The bioavailability of methylprednisolone from the 20 mg tablet was 0.82 +/- 0.11 (s.d.).,Methylprednisolone pharmacokinetics after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),,0.82,168304,DB00959,Methylprednisolone
,2655680,half-life,"4. In vivo hydrolysis of MPSS was rapid with a half-life of 4.14 +/- 1.62 (s.d.) min, and was independent of dose.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),min,4.14,168305,DB00959,Methylprednisolone
,23876165,Maximum measured plasma MPA concentrations,"Maximum measured plasma MPA concentrations were 6.06 ± 1.57 at 0.271 days (6.5 h; range: 5.0-7.92 h) and 6.27 ± 1.29 ng/mL at 0.276 days (6.6 h; range: 4.03-12.0 h) for horses that had synovial fluid collected (group 1) and those that did not (group 2), respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),,6.06,169094,DB00959,Methylprednisolone
,23876165,Maximum measured plasma MPA concentrations,"Maximum measured plasma MPA concentrations were 6.06 ± 1.57 at 0.271 days (6.5 h; range: 5.0-7.92 h) and 6.27 ± 1.29 ng/mL at 0.276 days (6.6 h; range: 4.03-12.0 h) for horses that had synovial fluid collected (group 1) and those that did not (group 2), respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),[ng] / [ml],6.27,169095,DB00959,Methylprednisolone
,23876165,plasma terminal half-life,"The plasma terminal half-life was 1.33 ± 0.80 and 0.843 ± 0.414 days for groups 1 and 2, respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),d,1.33,169096,DB00959,Methylprednisolone
,23876165,plasma terminal half-life,"The plasma terminal half-life was 1.33 ± 0.80 and 0.843 ± 0.414 days for groups 1 and 2, respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),d,0.843,169097,DB00959,Methylprednisolone
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],25.6,174693,DB00959,Methylprednisolone
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],17,174694,DB00959,Methylprednisolone
,26114223,apparent oral MDZ clearance,"In mixed model analysis, decreasing CYP3A4 activity, measured by apparent oral MDZ clearance (924 ± 443 ml min(-1) at day 7 vs.",Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[ml] / [min],924,174695,DB00959,Methylprednisolone
,15848561,saturation concentration,"Serum basiliximab concentrations declined to 0.16 microg/mL on day 33, which is below the IL-2R saturation concentration (0.2 microg/mL).",Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848561/),[μg] / [ml],0.2,177134,DB00959,Methylprednisolone
,15848561,elimination rate,Multiple sessions of plasmapheresis using DFPP enhanced the elimination of serum basiliximab at an average elimination rate of 19.1%.,Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848561/),%,19.1,177135,DB00959,Methylprednisolone
,15848561,saturation level,"In the patient reported on here, the serum basiliximab concentration fell to below the IL-2R saturation level (0.2 microg/mL) within 1 month of living-related kidney transplantation.",Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848561/),[μg] / [ml],0.2,177136,DB00959,Methylprednisolone
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],4805,177950,DB00959,Methylprednisolone
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],5917,177951,DB00959,Methylprednisolone
,11049012,time to the Cmax,Grapefruit juice delayed the time to the Cmax from 2.0 h to 3.0 h (P < 0.05).,Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049012/),h,2.0,181196,DB00959,Methylprednisolone
,11049012,time to the Cmax,Grapefruit juice delayed the time to the Cmax from 2.0 h to 3.0 h (P < 0.05).,Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049012/),h,3.0,181197,DB00959,Methylprednisolone
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],405,181655,DB00959,Methylprednisolone
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],373,181656,DB00959,Methylprednisolone
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.5,181657,DB00959,Methylprednisolone
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.3,181658,DB00959,Methylprednisolone
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.7,181659,DB00959,Methylprednisolone
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.6,181660,DB00959,Methylprednisolone
,29766530,apparent oral clearance (CL/F),"The typical values of apparent oral clearance (CL/F) and the apparent volume of distribution (V/F) in the final model were 2.05 L/h and 309 L, respectively.",Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29766530/),[l] / [h],2.05,183022,DB00959,Methylprednisolone
,29766530,apparent volume of distribution (V/F),"The typical values of apparent oral clearance (CL/F) and the apparent volume of distribution (V/F) in the final model were 2.05 L/h and 309 L, respectively.",Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29766530/),l,309,183023,DB00959,Methylprednisolone
,7599405,clearance,"During rejection episodes, the methylprednisolone clearance values were 523 +/- 154 ml/h/kg with a corresponding mean volume of distribution of 1.89 +/- 0.72 l/kg.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),[ml] / [h·kg],523,183935,DB00959,Methylprednisolone
,7599405,volume of distribution,"During rejection episodes, the methylprednisolone clearance values were 523 +/- 154 ml/h/kg with a corresponding mean volume of distribution of 1.89 +/- 0.72 l/kg.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),[l] / [kg],1.89,183936,DB00959,Methylprednisolone
,7599405,half-life,The mean methylprednisolone half-life was 2.61 +/- 0.62 h.,Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),h,2.61,183937,DB00959,Methylprednisolone
,7599405,clearance,"During Phase II, the methylprednisolone clearance was 358 +/- 95 ml/h/kg with a half-life of 3.05 h.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),[ml] / [h·kg],358,183938,DB00959,Methylprednisolone
,7599405,half-life,"During Phase II, the methylprednisolone clearance was 358 +/- 95 ml/h/kg with a half-life of 3.05 h.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),h,3.05,183939,DB00959,Methylprednisolone
,17325899,Overall response rate,"Overall response rate was 58%, with 37% complete and 21% partial responses.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),%,58,184793,DB00959,Methylprednisolone
,17325899,time to progression,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,5.7,184794,DB00959,Methylprednisolone
,17325899,overall median survival,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,14.5,184795,DB00959,Methylprednisolone
,9486490,terminal elimination half-life,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),h,18.2,185873,DB00959,Methylprednisolone
,9486490,total body clearance,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),[ml] / [h·kg],71,185874,DB00959,Methylprednisolone
,9486490,volume of distribution,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),[1] / [kg],1.67,185875,DB00959,Methylprednisolone
,9486490,bioavailability,The p.o. bioavailability was 31-49%.,Tacrolimus pharmacokinetics in BMT patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),%,31-49,185876,DB00959,Methylprednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],30.1,186660,DB00959,Methylprednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],31.1,186661,DB00959,Methylprednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],37.7,186662,DB00959,Methylprednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],35.7,186663,DB00959,Methylprednisolone
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],15.6,187089,DB00959,Methylprednisolone
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],21.5,187090,DB00959,Methylprednisolone
,15317828,a,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187091,DB00959,Methylprednisolone
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187092,DB00959,Methylprednisolone
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],46.4,187093,DB00959,Methylprednisolone
,15317828,AUC,"Despite chronic steroid therapy, 9 of 13 women had a normal cortisol profile and an ACTH AUC of 299 +/- 102 pg*h/mL.",Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·pg] / [ml],299,187094,DB00959,Methylprednisolone
,1541321,relative oral bioavailability,The relative oral bioavailability of the sterol was 69.2%.,High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541321/),%,69.2,187427,DB00959,Methylprednisolone
,1541321,mean residence times,"Elimination of methylprednisolone was prolonged when given orally; the mean residence times were 7.23 h and 3.94 h for oral and i.v. administrations, respectively.",High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541321/),h,7.23,187428,DB00959,Methylprednisolone
,1541321,mean residence times,"Elimination of methylprednisolone was prolonged when given orally; the mean residence times were 7.23 h and 3.94 h for oral and i.v. administrations, respectively.",High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541321/),h,3.94,187429,DB00959,Methylprednisolone
,9646011,elimination half-life,Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,1 and 3,187764,DB00959,Methylprednisolone
,9646011,half-life,Concentrations of ALBSO are highly variable between individuals and it has a half-life of between 6 and 15 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,6 and 15,187765,DB00959,Methylprednisolone
,9832298,systemic clearance,"During the acute phase, the systemic clearance of methylprednisolone was 0.98 (1 kg(-1) x h(-1)) and the elimination half-life was 1.67 h.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[1] / [h·kg],0.98,191717,DB00959,Methylprednisolone
,9832298,elimination half-life,"During the acute phase, the systemic clearance of methylprednisolone was 0.98 (1 kg(-1) x h(-1)) and the elimination half-life was 1.67 h.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,1.67,191718,DB00959,Methylprednisolone
,9832298,area under the plasma concentration-versus-time curve,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[h·mg] / [l],4.00,191719,DB00959,Methylprednisolone
,9832298,area under the plasma concentration-versus-time curve,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[h·mg] / [l],3.20,191720,DB00959,Methylprednisolone
,9832298,elimination half-life,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,3.51,191721,DB00959,Methylprednisolone
,9832298,elimination half-life,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,2.42,191722,DB00959,Methylprednisolone
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],25.2,193169,DB00959,Methylprednisolone
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],16.8,193170,DB00959,Methylprednisolone
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,2.28,193171,DB00959,Methylprednisolone
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,3.12,193172,DB00959,Methylprednisolone
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],871,193173,DB00959,Methylprednisolone
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],1299,193174,DB00959,Methylprednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.446,193175,DB00959,Methylprednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.780,193176,DB00959,Methylprednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],9.20,193177,DB00959,Methylprednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],10.7,193178,DB00959,Methylprednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],18.5,193179,DB00959,Methylprednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],20.9,193180,DB00959,Methylprednisolone
,7513355,Clearances,Clearances of MP were 0.45 liters/hr/kg after given alone and 0.48 liter/hr/kg after tracrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.45,200562,DB00959,Methylprednisolone
,7513355,Clearances,Clearances of MP were 0.45 liters/hr/kg after given alone and 0.48 liter/hr/kg after tracrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.48,200563,DB00959,Methylprednisolone
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.18,200564,DB00959,Methylprednisolone
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.21,200565,DB00959,Methylprednisolone
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.35,200566,DB00959,Methylprednisolone
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.21,200567,DB00959,Methylprednisolone
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.35,200568,DB00959,Methylprednisolone
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.19,200569,DB00959,Methylprednisolone
,7513355,IC50,MP and tacrolimus decreased the number of circulating helper-T cells with IC50 values of 23 ng/ml for MP and 6.7 ng/ml for tacrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],23,200570,DB00959,Methylprednisolone
,7513355,IC50,MP and tacrolimus decreased the number of circulating helper-T cells with IC50 values of 23 ng/ml for MP and 6.7 ng/ml for tacrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],6.7,200571,DB00959,Methylprednisolone
,7513355,IC50,The IC50 of tacrolimus for in vitro inhibition of lymphocyte proliferation was 0.39 ng/ml (0.47 nM) and 1.02 ng/ml (2.73 nM) for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],0.39,200572,DB00959,Methylprednisolone
,7513355,IC50,The IC50 of tacrolimus for in vitro inhibition of lymphocyte proliferation was 0.39 ng/ml (0.47 nM) and 1.02 ng/ml (2.73 nM) for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],1.02,200573,DB00959,Methylprednisolone
,7513355,maximum percentage of inhibition,The maximum percentage of inhibition was 94.6% for tacrolimus and 64.9% for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),%,94.6,200574,DB00959,Methylprednisolone
,7513355,maximum percentage of inhibition,The maximum percentage of inhibition was 94.6% for tacrolimus and 64.9% for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),%,64.9,200575,DB00959,Methylprednisolone
,15099443,half-life,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),min,15,200702,DB00959,Methylprednisolone
,15099443,inhibition constant,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),μM,32.4,200703,DB00959,Methylprednisolone
,7781199,clearance,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),[ml] / [h·kg],280,201017,DB00959,Methylprednisolone
,7781199,volume of distribution,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),[l] / [kg],1.1,201018,DB00959,Methylprednisolone
,7781199,t1/2,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),h,2.7,201019,DB00959,Methylprednisolone
,7781199,fraction unbound,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),,0.2,201020,DB00959,Methylprednisolone
,11187897,MTD,The MTD of cinchonine administered by continuous i.v. infusion was 30 mg/kg/d.,"Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11187897/),[mg] / [d·kg],30,204899,DB00959,Methylprednisolone
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],44.40,209031,DB00959,Methylprednisolone
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],158.01,209032,DB00959,Methylprednisolone
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],92.23,209033,DB00959,Methylprednisolone
,8272400,terminal half-life,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),h,0.48,214820,DB00959,Methylprednisolone
,8272400,terminal half-life,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),h,30.13,214821,DB00959,Methylprednisolone
,8272400,MRT,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),h,0.42 to 11.95,214822,DB00959,Methylprednisolone
,8272400,Vss,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),[l] / [kg],2.10 to 21.87,214823,DB00959,Methylprednisolone
,8272400,AUC,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),[h·ng] / [ml],339 to 1093,214824,DB00959,Methylprednisolone
,6338168,half-time,This rapid elimination phase was followed by a slower phase which paralleled the constant elimination rate from uninjured tissue of traumatized cord (approximate half-time = 6 hours).,Uptake and elimination of methylprednisolone from contused cat spinal cord following intravenous injection of the sodium succinate ester. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6338168/),h,6,216159,DB00959,Methylprednisolone
,455892,bioavailability,"The median value of bioavailability (relative to oral dose) of methylprednisolone acetate based on unchanged methylprednisolone plasma levels was 14.2% after rectal administration, suggesting that the drug exerts its therapeutic effect topically rather than systemically.",Rectal and oral absorption of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),%,14.2,217664,DB00959,Methylprednisolone
,455892,bioavailability,"Mean bioavailability (relative to oral administration of methylprednisolone acetate) of methylprednisolone after oral administration was 89.9%, indicating somewhat better systemic availability of the ester than the alcohol.",Rectal and oral absorption of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),%,89.9,217665,DB00959,Methylprednisolone
,455892,apparent elimination rate constant,"The average apparent elimination rate constant for methylprednisolone after oral administration of both ester and alcohol was 0.290 hr-1, corresponding to a half-life of 2.39 hr.",Rectal and oral absorption of methylprednisolone acetate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),1/[h],0.290,217666,DB00959,Methylprednisolone
,455892,half-life,"The average apparent elimination rate constant for methylprednisolone after oral administration of both ester and alcohol was 0.290 hr-1, corresponding to a half-life of 2.39 hr.",Rectal and oral absorption of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),h,2.39,217667,DB00959,Methylprednisolone
,10656433,maximum tolerated dose,The maximum tolerated dose determined during the first cycle was 1000 mg/m2/day for 5 days of 5FU with either 75 or 85 mg/m2 docetaxel.,A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10656433/),,1000,219020,DB00959,Methylprednisolone
,10886464,ka,A one-compartment open model with first-order absorption (ka for PKS=0. 5/h; ka for CAPCIL=0.3/h ) and first- order elimination.,Theophylline pharmacokinetics with concomitant steroid and gold therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886464/),1/[h],0. 5,221769,DB00959,Methylprednisolone
,10886464,ka,A one-compartment open model with first-order absorption (ka for PKS=0. 5/h; ka for CAPCIL=0.3/h ) and first- order elimination.,Theophylline pharmacokinetics with concomitant steroid and gold therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886464/),1/[h],0.3,221770,DB00959,Methylprednisolone
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,11.8 to 21.7,224538,DB00959,Methylprednisolone
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,45.6 to 130.3,224539,DB00959,Methylprednisolone
,3950871,systemic availability,"After intra-articular administration of MPA as a suspension (200 mg in toto), both MP and MPA decline very rapidly and, 24 hr after injection, less than 1% of the dose was present in the synovial fluid, but systemic availability of MP during the first 24 hr was only 30% of the dose.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),%,30,224540,DB00959,Methylprednisolone
,3950871,apparent half-time,"After this delay, the synovial fluid concentration decreased very slowly with an apparent half-time of 18 days.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),d,18,224541,DB00959,Methylprednisolone
,3312572,clearance,"In the normal state, the clearance of methylprednisolone succinate was 1.64 +/- 0.499 L/h/kg and its half-life was 15.33 +/- 3.84 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),[l] / [h·kg],1.64,224589,DB00959,Methylprednisolone
,3312572,half-life,"In the normal state, the clearance of methylprednisolone succinate was 1.64 +/- 0.499 L/h/kg and its half-life was 15.33 +/- 3.84 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),min,15.33,224590,DB00959,Methylprednisolone
,3312572,systemic availability,"The systemic availability of methylprednisolone from methylprednisolone succinate was 59.9 +/- 8.3%, and the maximal methylprednisolone concentration was observed after a delay of 7.68 +/- 6.31 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),%,59.9,224591,DB00959,Methylprednisolone
,3312572,clearance,"The clearance of methylprednisolone succinate decreased to 0.488 +/- 0.240 L/kg/h, and the half-life increased to 40.66 +/- 23.48 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),[l] / [h·kg],0.488,224592,DB00959,Methylprednisolone
,3312572,half-life,"The clearance of methylprednisolone succinate decreased to 0.488 +/- 0.240 L/kg/h, and the half-life increased to 40.66 +/- 23.48 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),min,40.66,224593,DB00959,Methylprednisolone
,17569107,terminal slope,MPL exhibited bi-exponential kinetics after i.v. dosing with a terminal slope of 2.1 h(-1).,Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17569107/),1/[h],2.1,224879,DB00959,Methylprednisolone
,17569107,first-order absorption rate constants,"The i.m. drug was absorbed slowly with two first-order absorption rate constants, 1.26 and 0.219 h(-1) indicating flip-flop kinetics with overall 50% bioavailability.",Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17569107/),1/[h],1.26,224880,DB00959,Methylprednisolone
,17569107,first-order absorption rate constants,"The i.m. drug was absorbed slowly with two first-order absorption rate constants, 1.26 and 0.219 h(-1) indicating flip-flop kinetics with overall 50% bioavailability.",Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17569107/),1/[h],0.219,224881,DB00959,Methylprednisolone
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.45,229623,DB00959,Methylprednisolone
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.39,229624,DB00959,Methylprednisolone
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],43,229967,DB00959,Methylprednisolone
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],42,229968,DB00959,Methylprednisolone
,7881703,AUCi.v.,"The geometric means of AUCi.v. and AUCtablet were 4,049 and 3,334 ng.h/ml, respectively.",Absolute bioavailability of a new high dose methylprednisolone tablet formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7881703/),[h·ng] / [ml],"4,049",230547,DB00959,Methylprednisolone
,7881703,AUCtablet,"The geometric means of AUCi.v. and AUCtablet were 4,049 and 3,334 ng.h/ml, respectively.",Absolute bioavailability of a new high dose methylprednisolone tablet formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7881703/),[h·ng] / [ml],"3,334",230548,DB00959,Methylprednisolone
,7881703,absolute bioavailability,"The absolute bioavailability of the tablet product was 82%, which is in agreement with published data for other oral dosage forms of methylprednisolone.",Absolute bioavailability of a new high dose methylprednisolone tablet formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7881703/),%,82,230549,DB00959,Methylprednisolone
,6507464,bioavailability,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),%,74 to 81,233352,DB00959,Methylprednisolone
,6507464,plasma clearance,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),[l] / [h],22 to 24,233353,DB00959,Methylprednisolone
,3234253,Oral bioavailability,"Oral bioavailability was essentially 100 percent, ruling out impaired absorption.",Rapid methylprednisolone clearance in a patient with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234253/),%,100,234170,DB00959,Methylprednisolone
,1340442,half-life,"After intravenous infusion, methylprednisolone hemisuccinate was rapidly converted to methylprednisolone with a half-life of about 20 min.",Pharmacokinetics of high-dose methylprednisolone in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),min,20,234275,DB00959,Methylprednisolone
,1340442,mean residence time,"Methylprednisolone in serum, eliminated monoexponentially in 8 patients and biexponentially in the remaining three, had the mean residence time of about 3 h, and a terminal half-life of 2.5 h.",Pharmacokinetics of high-dose methylprednisolone in children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),h,3,234276,DB00959,Methylprednisolone
,1340442,terminal half-life,"Methylprednisolone in serum, eliminated monoexponentially in 8 patients and biexponentially in the remaining three, had the mean residence time of about 3 h, and a terminal half-life of 2.5 h.",Pharmacokinetics of high-dose methylprednisolone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),h,2.5,234277,DB00959,Methylprednisolone
,1340442,volume of distribution at steady state,"The volume of distribution at steady state, and the clearance were 1.3 liters/kg and 0.5 liters/kg/h, respectively.",Pharmacokinetics of high-dose methylprednisolone in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),[l] / [kg],1.3,234278,DB00959,Methylprednisolone
,1340442,clearance,"The volume of distribution at steady state, and the clearance were 1.3 liters/kg and 0.5 liters/kg/h, respectively.",Pharmacokinetics of high-dose methylprednisolone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),[l] / [h·kg],0.5,234279,DB00959,Methylprednisolone
,10517356,flow-rate,The flow-rate was 1.5 ml/min and UV detection was achieved at 248 nm.,"High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),[ml] / [min],1.5,238744,DB00959,Methylprednisolone
,10517356,half-life,"The half-life of prodrug methylprednisolone-21-hemisuccinate (MPS) was 0.3 h, that of metabolite MPX (21-carboxy MP) was 0.4 h and that of the parent drug methylprednisolone (MP) was 1.4 h.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,0.3,238745,DB00959,Methylprednisolone
,10517356,half-life,"The half-life of prodrug methylprednisolone-21-hemisuccinate (MPS) was 0.3 h, that of metabolite MPX (21-carboxy MP) was 0.4 h and that of the parent drug methylprednisolone (MP) was 1.4 h.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,0.4,238746,DB00959,Methylprednisolone
,10517356,half-life,"The half-life of prodrug methylprednisolone-21-hemisuccinate (MPS) was 0.3 h, that of metabolite MPX (21-carboxy MP) was 0.4 h and that of the parent drug methylprednisolone (MP) was 1.4 h.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,1.4,238747,DB00959,Methylprednisolone
,10517356,half-lives,The half-lives of the metabolites are almost similar (4 h).,"High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,4,238748,DB00959,Methylprednisolone
,10517356,renal clearance,"The renal clearance values of metabolites MPB, MPC and MPD are approximately 500 ml/min, that of MP is 100 ml/min.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),[ml] / [min],500,238749,DB00959,Methylprednisolone
,10517356,renal clearance,"The renal clearance values of metabolites MPB, MPC and MPD are approximately 500 ml/min, that of MP is 100 ml/min.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),[ml] / [min],100,238750,DB00959,Methylprednisolone
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],90.9,239639,DB00959,Methylprednisolone
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],64.7,239640,DB00959,Methylprednisolone
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[ml] / [min],87.3,239641,DB00959,Methylprednisolone
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),,120.6,239642,DB00959,Methylprednisolone
,15487809,concentration,"At steady state, the average measured MP concentration in plasma was 12.3+/-7.0 microg/ml and 1.74+/-0.85 microg/ml in CSF.",Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487809/),[μg] / [ml],12.3,241566,DB00959,Methylprednisolone
,15487809,concentration,"At steady state, the average measured MP concentration in plasma was 12.3+/-7.0 microg/ml and 1.74+/-0.85 microg/ml in CSF.",Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487809/),[μg] / [ml],1.74,241567,DB00959,Methylprednisolone
,10758783,AUC0-infinity,Values of 342.53 ng.h/ml (test preparation) and 336.61 ng.h/ml (reference preparation) for the parameter AUC0-infinity demonstrate an nearly identical extent of drug absorption.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[h·ng] / [ml],342.53,243124,DB00959,Methylprednisolone
,10758783,AUC0-infinity,Values of 342.53 ng.h/ml (test preparation) and 336.61 ng.h/ml (reference preparation) for the parameter AUC0-infinity demonstrate an nearly identical extent of drug absorption.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[h·ng] / [ml],336.61,243125,DB00959,Methylprednisolone
,10758783,Maximum concentrations (Cmax),Maximum concentrations (Cmax) of 66.58 ng/ml and 70.51 ng/ml were achieved for test and reference preparation.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[ng] / [ml],66.58,243126,DB00959,Methylprednisolone
,10758783,Maximum concentrations (Cmax),Maximum concentrations (Cmax) of 66.58 ng/ml and 70.51 ng/ml were achieved for test and reference preparation.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[ng] / [ml],70.51,243127,DB00959,Methylprednisolone
,10758783,Time to reach maximum plasma concentration (tmax),Time to reach maximum plasma concentration (tmax) was 2.2 h for both preparations.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),h,2.2,243128,DB00959,Methylprednisolone
,7886801,clearance,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ml] / [h·kg],206,243352,DB00959,Methylprednisolone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[l] / [kg],0.95,243353,DB00959,Methylprednisolone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ml] / [h·kg],327,243354,DB00959,Methylprednisolone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[l] / [kg],1.33,243355,DB00959,Methylprednisolone
,7886801,total cortisol,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],732,243356,DB00959,Methylprednisolone
,7886801,AUC,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],732,243357,DB00959,Methylprednisolone
,7886801,AUC,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],539,243358,DB00959,Methylprednisolone
,7886801,suppression half-life,The mean cortisol suppression half-life was 4.31 +/- 1.54 hr in black recipients and 4.11 +/- 1.49 hr in whites (P = 0.48).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),h,4.31,243359,DB00959,Methylprednisolone
,7886801,suppression half-life,The mean cortisol suppression half-life was 4.31 +/- 1.54 hr in black recipients and 4.11 +/- 1.49 hr in whites (P = 0.48).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),h,4.11,243360,DB00959,Methylprednisolone
,7886801,AUC,The mean return cortisol AUC for the black patients was 327 +/- 279 ng.hr/ml and 370 +/- 207 ng.hr/ml for white patients (P = 0.28).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],327,243361,DB00959,Methylprednisolone
,7886801,AUC,The mean return cortisol AUC for the black patients was 327 +/- 279 ng.hr/ml and 370 +/- 207 ng.hr/ml for white patients (P = 0.28).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],370,243362,DB00959,Methylprednisolone
,7886801,nadir,"The serum cortisol nadir for black patients was 12.3 +/- 7.2 ng/ml, which was significantly higher than the cortisol nadir in white patients (6.4 +/- 4.4 ng/ml; P = 0.03).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ng] / [ml],12.3,243363,DB00959,Methylprednisolone
,7886801,nadir,"The serum cortisol nadir for black patients was 12.3 +/- 7.2 ng/ml, which was significantly higher than the cortisol nadir in white patients (6.4 +/- 4.4 ng/ml; P = 0.03).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ng] / [ml],6.4,243364,DB00959,Methylprednisolone
,18240180,AUC,There was a trend toward significance in difference in mean AUC of IVMP (116.72 microg x ml/hour) compared with OP (65.16 microg x ml/hour; P = 0.059).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[ml·μg] / [h],116.72,244401,DB00959,Methylprednisolone
,18240180,AUC,There was a trend toward significance in difference in mean AUC of IVMP (116.72 microg x ml/hour) compared with OP (65.16 microg x ml/hour; P = 0.059).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[ml·μg] / [h],65.16,244402,DB00959,Methylprednisolone
,18240180,peak concentration,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[μg] / [ml],34.49,244403,DB00959,Methylprednisolone
,18240180,peak concentration,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[μg] / [ml],7.08,244404,DB00959,Methylprednisolone
,18240180,half-life,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),h,1.90,244405,DB00959,Methylprednisolone
,18240180,half-life,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),h,2.36,244406,DB00959,Methylprednisolone
,7628493,plasma/CSF ratio,Passage of MP into the CSF was delayed since mean plasma/CSF ratio dropped dramatically from 150 at the 2nd h to 25 at the 3rd h after starting infusion.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),,150,245156,DB00959,Methylprednisolone
,7628493,plasma/CSF ratio,Passage of MP into the CSF was delayed since mean plasma/CSF ratio dropped dramatically from 150 at the 2nd h to 25 at the 3rd h after starting infusion.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),,25,245157,DB00959,Methylprednisolone
,7628493,CSF,CSF concentrations of MP were high with a mean reaching 522 micrograms/l at the 6th h.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),[μg] / [l],522,245158,DB00959,Methylprednisolone
,7628493,concentrations,CSF concentrations of MP were high with a mean reaching 522 micrograms/l at the 6th h.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),[μg] / [l],522,245159,DB00959,Methylprednisolone
,8117404,t1/2 alpha,The mean t1/2 alpha was 0.5 h (range 0.1-1.1 h) and the mean t1/2 beta 2.4 h (range 1.0-5.9 h).,Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8117404/),h,0.5,248768,DB00959,Methylprednisolone
,8117404,t1/2 beta,The mean t1/2 alpha was 0.5 h (range 0.1-1.1 h) and the mean t1/2 beta 2.4 h (range 1.0-5.9 h).,Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8117404/),h,2.4,248769,DB00959,Methylprednisolone
,8117404,Cmax,The mean Cmax was 4117 ng/ml (range 1944-7166 ng/ml) and the mean AUC 12505 ng.,Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8117404/),[ng] / [ml],4117,248770,DB00959,Methylprednisolone
,8117404,AUC,The mean Cmax was 4117 ng/ml (range 1944-7166 ng/ml) and the mean AUC 12505 ng.,Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8117404/),ng,12505,248771,DB00959,Methylprednisolone
,8117404,Clearance,Clearance ranged from 375 to 945 ml/min (mean 653 ml/min) and volume of distribution ranged from 0.2 to 1.4 l/kg (mean 0.7 l/kg).,Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8117404/),[ml] / [min],653,248772,DB00959,Methylprednisolone
,8117404,volume of distribution,Clearance ranged from 375 to 945 ml/min (mean 653 ml/min) and volume of distribution ranged from 0.2 to 1.4 l/kg (mean 0.7 l/kg).,Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8117404/),[l] / [kg],0.7,248773,DB00959,Methylprednisolone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],2773,252860,DB00959,Methylprednisolone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],7011,252861,DB00959,Methylprednisolone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,3.2,252862,DB00959,Methylprednisolone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,5.5,252863,DB00959,Methylprednisolone
,9469676,total systemic clearance,The total systemic clearance of methylprednisolone was significantly less in acutely injured patients (mean +/- SD 30.04 +/- 12.03 L/hr) than in historically reported able-bodied controls (44.70 +/- 4.90 L/hr).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),[l] / [h],30.04,256958,DB00959,Methylprednisolone
,9469676,total systemic clearance,The total systemic clearance of methylprednisolone was significantly less in acutely injured patients (mean +/- SD 30.04 +/- 12.03 L/hr) than in historically reported able-bodied controls (44.70 +/- 4.90 L/hr).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),[l] / [h],44.70,256959,DB00959,Methylprednisolone
,9469676,volume of distribution,No differences in volume of distribution were discernible between patients (126.90 L) and controls (135.45 L).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),l,126.90,256960,DB00959,Methylprednisolone
,9469676,volume of distribution,No differences in volume of distribution were discernible between patients (126.90 L) and controls (135.45 L).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),l,135.45,256961,DB00959,Methylprednisolone
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],1968,258033,DB00959,Methylprednisolone
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],520,258034,DB00959,Methylprednisolone
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],221,258035,DB00959,Methylprednisolone
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],118,258036,DB00959,Methylprednisolone
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,4.4,258037,DB00959,Methylprednisolone
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,1.9,258038,DB00959,Methylprednisolone
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],18,258039,DB00959,Methylprednisolone
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],139,258040,DB00959,Methylprednisolone
,6968763,total body clearance,Baseline total body clearance of methylprednisolone was 406 +/- 139 (mean +/- SD) ml/min/1.73 m2 and decreased significantly (p < 0.001) to 146 +/- 57 ml/min/1.73 m2 1 wk after TAO therapy was initiated.,The effect of troleandomycin on methylprednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),[ml] / [1.73·m2·min],406,258381,DB00959,Methylprednisolone
,6968763,total body clearance,Baseline total body clearance of methylprednisolone was 406 +/- 139 (mean +/- SD) ml/min/1.73 m2 and decreased significantly (p < 0.001) to 146 +/- 57 ml/min/1.73 m2 1 wk after TAO therapy was initiated.,The effect of troleandomycin on methylprednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),[ml] / [1.73·m2·min],146,258382,DB00959,Methylprednisolone
,6968763,half-life,Methylprednisolone half-life was 2.46 +/- 0.75 hr before TAO and increased significantly (p < 0.01) to 4.63 +/- 1.35 hr after 1 wk on TAO therapy.,The effect of troleandomycin on methylprednisolone elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),h,2.46,258383,DB00959,Methylprednisolone
,6968763,half-life,Methylprednisolone half-life was 2.46 +/- 0.75 hr before TAO and increased significantly (p < 0.01) to 4.63 +/- 1.35 hr after 1 wk on TAO therapy.,The effect of troleandomycin on methylprednisolone elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),h,4.63,258384,DB00959,Methylprednisolone
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB00959,Methylprednisolone
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB00959,Methylprednisolone
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB00959,Methylprednisolone
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB00959,Methylprednisolone
,9205819,bioavailability,The bioavailability of MP was equivalent when based on AUC with a MP suleptanate median 108% of the MP succinate value (90% CI: 102-114%).,Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205819/),%,108,267933,DB00959,Methylprednisolone
,7930339,serum concentration,"However, 4 hours after the dose, the mean serum concentration of methylprednisolone was 50.9 +/- 15.1 ng/mL in the elderly group and 37.6 +/- 7.5 (P = 0.07) ng/mL in the young group.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ng] / [ml],50.9,269107,DB00959,Methylprednisolone
,7930339,serum concentration,"However, 4 hours after the dose, the mean serum concentration of methylprednisolone was 50.9 +/- 15.1 ng/mL in the elderly group and 37.6 +/- 7.5 (P = 0.07) ng/mL in the young group.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ng] / [ml],37.6,269108,DB00959,Methylprednisolone
,7930339,clearance,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ml] / [h·kg],237,269109,DB00959,Methylprednisolone
,7930339,volume of distribution,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[l] / [kg],1.10,269110,DB00959,Methylprednisolone
,7930339,drug clearance,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ml] / [h·kg],359,269111,DB00959,Methylprednisolone
,7930339,volume of distribution,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[l] / [kg],1.28,269112,DB00959,Methylprednisolone
,7930339,half-life,The half-life of methylprednisolone ranged from 1.90 to 5.40 hours in the elderly group; the range was 1.99 to 3.31 hour (P = 0.016) in the young group.,Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),h,1.90 to 5.40,269113,DB00959,Methylprednisolone
,7930339,half-life,The half-life of methylprednisolone ranged from 1.90 to 5.40 hours in the elderly group; the range was 1.99 to 3.31 hour (P = 0.016) in the young group.,Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),h,1.99 to 3.31,269114,DB00959,Methylprednisolone
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,49-57,271663,DB00959,Methylprednisolone
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,35,271664,DB00959,Methylprednisolone
,1545348,Apparent systemic clearance (CL),"Apparent systemic clearance (CL) of methylprednisolone was 21 mL/min (low dose), approximately twice the liver blood flow.",Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),[ml] / [min],21,271665,DB00959,Methylprednisolone
,16463770,half-life time,"The half-life time of MTH in perilymph after otocyst was infused was 1.51 h, and the one after niche was placed with granule gelfoam soaked with MTH was 1.55 h.",[Methylprednisolone pharmacokinetics in perilymph and plasma of guinea pig after topical administration and intracardial injection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463770/),h,1.51,272545,DB00959,Methylprednisolone
,16463770,half-life time,"The half-life time of MTH in perilymph after otocyst was infused was 1.51 h, and the one after niche was placed with granule gelfoam soaked with MTH was 1.55 h.",[Methylprednisolone pharmacokinetics in perilymph and plasma of guinea pig after topical administration and intracardial injection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463770/),h,1.55,272546,DB00959,Methylprednisolone
,7756707,total body clearance,"The mean +/- SD total body clearance in study 1 was 363 +/- 330 mL/min/kg, whereas the mean volume of distribution was 1.18 +/- 0.53 L/kg.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[ml] / [kg·min],363,273996,DB00959,Methylprednisolone
,7756707,volume of distribution,"The mean +/- SD total body clearance in study 1 was 363 +/- 330 mL/min/kg, whereas the mean volume of distribution was 1.18 +/- 0.53 L/kg.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[l] / [kg],1.18,273997,DB00959,Methylprednisolone
,7756707,elimination rate constant,"The mean elimination rate constant was 0.29 +/- 0.14 h-1, with a mean serum half-life of 2.87 +/- 1.15 h during the first phase.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),1/[h],0.29,273998,DB00959,Methylprednisolone
,7756707,serum half-life,"The mean elimination rate constant was 0.29 +/- 0.14 h-1, with a mean serum half-life of 2.87 +/- 1.15 h during the first phase.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),h,2.87,273999,DB00959,Methylprednisolone
,7756707,clearance,"In study 2, the mean methylprednisolone clearance was 261 +/- 150 mL/min/kg (p > 0.05) and the mean volume of distribution was 0.89 +/- 0.31 L/kg (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[ml] / [kg·min],261,274000,DB00959,Methylprednisolone
,7756707,volume of distribution,"In study 2, the mean methylprednisolone clearance was 261 +/- 150 mL/min/kg (p > 0.05) and the mean volume of distribution was 0.89 +/- 0.31 L/kg (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[l] / [kg],0.89,274001,DB00959,Methylprednisolone
,7756707,serum half-life,"The mean serum half-life of methylprednisolone was 2.91 +/- 0.60 h (p > 0.05), with the mean elimination rate constant of 0.25 +/- 0.06 h-1 (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),h,2.91,274002,DB00959,Methylprednisolone
,7756707,elimination rate constant,"The mean serum half-life of methylprednisolone was 2.91 +/- 0.60 h (p > 0.05), with the mean elimination rate constant of 0.25 +/- 0.06 h-1 (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),1/[h],0.25,274003,DB00959,Methylprednisolone
